BS_74FS6GMW
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 11.432325886990801
- age_years
- 0.797
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.694
- MYC_TARGETS_V1+0.660
- E2F_TARGETS+0.628
- G2M_CHECKPOINT+0.537
- MTORC1_SIGNALING+0.338
- UNFOLDED_PROTEIN_RESPONSE+0.306
- DNA_REPAIR+0.299
- OXIDATIVE_PHOSPHORYLATION+0.274
- GLYCOLYSIS+0.259
- PANCREAS_BETA_CELLS+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.457
- ALLOGRAFT_REJECTION-0.445
- IL6_JAK_STAT3_SIGNALING-0.429
- INTERFERON_GAMMA_RESPONSE-0.423
- MYOGENESIS-0.370
- INFLAMMATORY_RESPONSE-0.355
- KRAS_SIGNALING_UP-0.341
- UV_RESPONSE_DN-0.306
- COMPLEMENT-0.305
- HEDGEHOG_SIGNALING-0.258
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.911 |
| 2 | BS_MDBT7S5Z | high-grade glioma | — | 0.900 |
| 3 | X7c81e3d9.c538.468a.8a2a.f34513bac230 | — | cohortA3 | 0.897 |
| 4 | 20020032.TNBC | — | E | 0.895 |
| 5 | C3L-01285 | — | cohortSQ2 | 0.893 |
| 6 | BS_0HW7W7SD | Embryonal tumors | — | 0.893 |
| 7 | BS_MV6ASWV9 | ATRT | — | 0.892 |
| 8 | SRR8518170 | — | E | 0.883 |
| 9 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.883 |
| 10 | C3N-01411 | — | cohortSQ2 | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.694 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.660 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.628 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.537 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.338 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.306 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.299 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.274 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.259 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.189 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.121 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.119 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.102 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.096 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.087 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.038 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.032 | Remibrutinib | — uncovered |
| PEROXISOME | 0.013 | Idelalisib | — uncovered |